Immunomedics Inc Revenue Growth Rates (IMMU), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immunomedics Inc   (NASDAQ: IMMU)
 

IMMU's Revenue Growth by Quarter and Year

Immunomedics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMMU Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 20.07
1st Quarter March 0.00
FY 20.07

IMMUs Annual Revenue
Immunomedics Inc 's Revenue in the fiscal year 2019 $ 0.30 millions
Immunomedics Inc 's Revenue in the fiscal year 2018 $ 2.16 millions
Immunomedics Inc 's Revenue in the fiscal year 2017 $ 3.09 millions
Immunomedics Inc 's Revenue in the fiscal year 2016 $ 3.23 millions
Immunomedics Inc 's Revenue in the fiscal year 2015 $ 5.65 millions




IMMU Revenue second quarter 2020 Y/Y Growth Comment
Immunomedics Inc in the second quarter 2020 achieved Revenue of $ 20.07 millions compare to recorded in same quarter a year ago.

According to the results reported in the second quarter 2020, Immunomedics Inc achieved the best Revenue growth in In Vitro & In Vivo Diagnostic Substances industry. While Immunomedics Inc ' s Revenue no change of 0% ranks overall at the positon no. in the second quarter 2020.


IMMU Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - -72.22 % 80 % 57.89 %
3rd Quarter September - - - -6.76 %
2nd Quarter June - - -39.06 % -31.18 %
1st Quarter March - - -63.64 % 46.67 %
FY   - -84.62 % -40 % -

Financial Statements
Immunomedics Inc 's second quarter 2020 Revenue $ 20.07 millions IMMU's Income Statement
Immunomedics Inc 's second quarter 2019 Revenue $ 0.00 millions Quarterly IMMU's Income Statement


IMMU Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - - - -13.04 %
3rd Quarter September - - - 7.81 %
2nd Quarter June - - -18.75 % -51.52 %
1st Quarter March - - -20 % 247.37 %
FY (Year on Year)   - -84.62 % -40 % -


Back to IMMU Growth rate Comparisons >> Back to IMMU Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Immunomedics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMMU's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMMU's II. Quarter Q/Q Revenue Comment


Immunomedics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jun 30 2020 period, Immunomedics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Immunomedics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2020 period, Immunomedics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Immunomedics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMMU's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Integrated Biopharma Inc-0.36%$ -0.361 millions
Conformis inc -0.64%$ -0.638 millions
Nrc Health-0.79%$ -0.789 millions
Chimerix Inc -0.99%$ -0.989 millions
Prestige Consumer Healthcare Inc -1.19%$ -1.189 millions
Amedisys Inc-1.61%$ -1.608 millions
Sanara Medtech Inc -1.67%$ -1.667 millions
Endo International Plc-1.73%$ -1.735 millions
Sunlink Health Systems Inc -1.93%$ -1.927 millions
Novo Nordisk A-1.96%$ -1.960 millions
Healthcare Services Group Inc -2.18%$ -2.180 millions
Eli Lilly And Company-2.44%$ -2.436 millions
Myomo Inc -2.47%$ -2.472 millions
Icu Medical Inc-2.85%$ -2.851 millions
Reliv International Inc-2.91%$ -2.912 millions
Quanterix Corporation-3.00%$ -2.999 millions
United Therapeutics Corporation-3.10%$ -3.105 millions
Immunogen inc -3.33%$ -3.326 millions
Hologic Inc-3.46%$ -3.461 millions
Avantor Inc -3.50%$ -3.504 millions
Nature s Sunshine Products inc -3.79%$ -3.790 millions
American Renal Associates Holdings Inc -3.80%$ -3.800 millions
Healthlynked Corp-3.88%$ -3.880 millions
Labcorp Holdings Inc -3.92%$ -3.918 millions
Steris Plc-4.00%$ -4.000 millions
Mylan N v -4.22%$ -4.219 millions
Medpace Holdings Inc -4.25%$ -4.254 millions
Baxter International Inc -4.30%$ -4.296 millions
Pra Health Sciences Inc -4.38%$ -4.378 millions
Universal Health Services Inc -4.39%$ -4.393 millions


About Immunomedics Inc Revenue Growth Rates (IMMU), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.